These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23226787)

  • 1. PAI-1 promoter 4G/5G polymorphism (rs1799768) contributes to tumor susceptibility: Evidence from meta-analysis.
    Xu X; Xie Y; Lin Y; Xu X; Zhu Y; Mao Y; Hu Z; Wu J; Chen H; Zheng X; Qin J; Xie L
    Exp Ther Med; 2012 Dec; 4(6):1127-1133. PubMed ID: 23226787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Plasminogen Activator Inhibitor-1 Genetic Polymorphisms and Stroke Susceptibility.
    Hu X; Zan X; Xie Z; Li Y; Lin S; Li H; You C
    Mol Neurobiol; 2017 Jan; 54(1):328-341. PubMed ID: 26742513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PAI-1 4G/5G polymorphism contributes to cancer susceptibility: evidence from meta-analysis.
    Wang S; Cao Q; Wang X; Li B; Tang M; Yuan W; Fang J; Qian J; Qin C; Zhang W
    PLoS One; 2013; 8(2):e56797. PubMed ID: 23437240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between PAI-1 4G/5G polymorphism and diabetic nephropathy: a meta-analysis in the Chinese population.
    Gao WF; Guo YB; Bai Y; Ding XY; Yan YJ; Wu ZQ
    Int Urol Nephrol; 2016 Sep; 48(9):1483-9. PubMed ID: 27272255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The -675 4G/5G polymorphism in plasminogen activator inhibitor-1 gene is associated with risk of asthma: a meta-analysis.
    Nie W; Li B; Xiu QY
    PLoS One; 2012; 7(3):e34385. PubMed ID: 22479620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasminogen Activator Inhibitor-1 4G/5G Polymorphism Contributes to Osteonecrosis of the Femoral Head Susceptibility: Evidence from a Systematic Review and Meta-analysis.
    Sobhan MR; Mahdinezhad-Yazdi M; Moghimi M; Aghili K; Jafari M; Zare-Shehneh M; Neamatzadeh H
    Arch Bone Jt Surg; 2018 Nov; 6(6):468-477. PubMed ID: 30637301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphisms and risk of venous thromboembolism - a meta-analysis and systematic review.
    Zhang Q; Jin Y; Li X; Peng X; Peng N; Song J; Xu M
    Vasa; 2020 Mar; 49(2):141-146. PubMed ID: 31920171
    [No Abstract]   [Full Text] [Related]  

  • 8. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and risk of venous thromboembolism: a meta-analysis.
    Wang J; Wang C; Chen N; Shu C; Guo X; He Y; Zhou Y
    Thromb Res; 2014 Dec; 134(6):1241-8. PubMed ID: 25450536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-analysis of the association between plasminogen activator inhibitor-1 4G/5G polymorphism and recurrent pregnancy loss.
    Li X; Liu Y; Zhang R; Tan J; Chen L; Liu Y
    Med Sci Monit; 2015 Apr; 21():1051-6. PubMed ID: 25862335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with coronary artery disease risk: a meta-analysis.
    Zhang H; Dong P; Yang X; Liu Z
    Int J Clin Exp Med; 2014; 7(10):3777-88. PubMed ID: 25419432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and risk of Alzheimer's disease, metabolic syndrome, and female infertility: A meta-analysis.
    Zhang X; Gao B; Xu B
    Medicine (Baltimore); 2020 Dec; 99(50):e23660. PubMed ID: 33327353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Association of Plasminogen Activator Inhibitor Type 1 (PAI-1) Level and PAI-1 4G/5G Gene Polymorphism with the Formation and the Grade of Endometrial Cancer.
    Yıldırım ME; Karakuş S; Kurtulgan HK; Kılıçgün H; Erşan S; Bakır S
    Biochem Genet; 2017 Aug; 55(4):314-321. PubMed ID: 28303356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between plasminogen activator inhibitor-1 -675 4G/5G polymorphism and sepsis: a meta-analysis.
    Li L; Nie W; Zhou H; Yuan W; Li W; Huang W
    PLoS One; 2013; 8(1):e54883. PubMed ID: 23382992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasminogen Activator Inhibitor-1 Polymorphism Confers a Genetic Contribution to the Risk of Recurrent Spontaneous Abortion: An Updated Meta-Analysis.
    Huang Z; Tang W; Liang Z; Chen Q; Li M; Li Y; Lao S; Pan H; Huang L; Huang M; Hu X; Zhao J
    Reprod Sci; 2017 Nov; 24(11):1551-1560. PubMed ID: 28395596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAI-1 Polymorphisms Have Significant Associations With Cancer Risk, Especially Feminine Cancer.
    Wang J; Peng Y; Guo H; Li C
    Technol Cancer Res Treat; 2021; 20():15330338211037813. PubMed ID: 34521295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of tissue plasminogen activator and plasminogen activator inhibitor polymorphism with myocardial infarction: a meta-analysis.
    Gong LL; Peng JH; Han FF; Zhu J; Fang LH; Wang YH; Du GH; Wang HY; Liu LH
    Thromb Res; 2012 Sep; 130(3):e43-51. PubMed ID: 22771216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasminogen activator inhibitor-1 -675 4G/5G polymorphism and polycystic ovary syndrome risk: a meta analysis.
    Liu Y; Sun MG; Jiang R; Ding R; Che Z; Chen YY; Yao CJ; Zhu XX; Cao JY
    J Assist Reprod Genet; 2014 Mar; 31(3):363-70. PubMed ID: 24435452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasminogen activator inhibitor-1 4G/5G and the MTHFR 677C/T polymorphisms and susceptibility to polycystic ovary syndrome: a meta-analysis.
    Lee YH; Song GG
    Eur J Obstet Gynecol Reprod Biol; 2014 Apr; 175():8-14. PubMed ID: 24439532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasminogen activator inhibitor-1 4G/5G polymorphism and retinopathy risk in type 2 diabetes: a meta-analysis.
    Zhang T; Pang C; Li N; Zhou E; Zhao K
    BMC Med; 2013 Jan; 11():1. PubMed ID: 23281898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PAI-1 promoter polymorphism modulates uPA-PAI complex accumulation by breast cancer cells.
    Alvarez-Millán JJ; Bocos C; Ferrín V; Lucas AR; Ruibal A; Schneider J
    Oncology; 2002; 62(3):286-90. PubMed ID: 12065877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.